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Efficient and high yielding methods for the preparation of vildagliptin 1 intermediate of (S)-1-(2-chloroacetyl) 
pyrrolidine-2-carbonitrile 2 and 3-amino-1-adamantane alcohol 3 respectively have been described. (S)-1-(2-Chloroacetyl) 
pyrrolidine-2-carbonitrile 2 has been synthesized from L-proline 2a via chloroacetyl chloride, performed with acetonitrile in 
the presence of sulfuric acid via one-pot reactions. 3-Amino-1-adamantane alcohol 3 has been prepared from amantadine 
hydrochloride via oxidation by sulfuric acid/nitric acid and boric acid as catalyst, and has been subjected to ethanol 
extraction. The overall yield is about 95%.  
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Diabetes has been one of the three major threats to 
human health in the 21st century, which is a long-
term and chronic metabolic disease that has seriously 
effect patient’s quality of life. In recent years, the 
incidence of diabetes has increased rapidly. 
According to the data, up to 2017, there were about 
425 million people suffered from diabetes all over the 
world. In addition, this number is still on the rise and 
even up to 629 million in 2040
1
. Vildagliptin 1, 
designed by Novartis
2
, is a highly potent, reversible, 
orally active dipeptidyl peptidase IV (DPP-IV) 
inhibitor for the treatment of type 2 diabetes. It was 
announced that vildagliptin 1 had obtained the 
European Commission approval to be marketed in 
2008, under the trade name of Galvus
3
. Compared 
with the traditional oral hypoglycemic agents, 
vildagliptin 1 had less side effect
4
, high drug safety
5
, 




With the dramatic increase in the number of 
diabetics, the demand for vildagliptin 1 would 
continue to increase. However, the price of 
vildagliptin 1 is so expensive due to the low yield of 
the important intermediates that ordinary diabetics 
could not afford it. Therefore, it is a great of 
significance to improve the synthesis process of 
vildagliptin intermediates by using cheap raw 
materials and reagents. 
The 3-amino-1-adamantane alcohol 3 and cyano 
pyrrolidine moiety 2 has been found to be an integral 
part because of the key role in vidagliptin 1 (Scheme I)
8
. 
In the terms of the relevant literatures, synthetic methods 
of these intermediates almost have disadvantages of 
expensive raw materials
9,10
, complex synthetic 
routes
11,12
, as well as low yields
11
. Therefore it is 
necessary to develop a simple method with good yield in 
order to obtain vildagliptin intermediates quickly. 
In this context, synthesis of corresponding nitriles 
from carboxylic acids is not always a simple 
procedure. We found a facile step one-pot 
transformation of (S)-1-(2-chloroacetyl) pyrrolidine-
2-carboxylic acid 2b into nitriles by performing with 
acetonitrile in the presence of sulfuric acid 
(Scheme II)
13
. In addition, we were also synthesis of 
3-amino-1-adamantane alcohol 3, and was prepared 
from amantadine hydrochloride via oxidation by 
sulfuric acid/nitric acid (H2SO4/HNO3) and boric acid 
(H3BO3) as catalyst, then the mixture was treated with 
hydrolysis, acidification. Finally, the mixture was 
extracted by ethanol extraction technology to get the 
target compound and the total yield was 95% 
(Scheme III). 
Results and Discussion 
In our strategy (Scheme II), we decided to use L-
proline  2a   as  raw  material on  account  of  its  easy 




availability. Furthermore, we predicted that the 
chloroacetyl group could play a role in protecting 
effect and its removal could also be avoided. In our 
synthetic scheme, L-proline 2a was N-acylated with 
chloroacetyl chloride in refluxing THF to obtain 
carboxylic acid pyrrolidine moiety 2b. Then we 
observed that N-acylation of L-proline proceeds faster 
in solvent of THF at 70°C
14
. After all, many methods 
might convert carboxylic acids into nitriles which 
consist of two or more steps
15-17
. Therefore, firstly, we 
attempted to convert the carboxylic acid moiety 
(compound 2b) to the amide, and subsequently 
conversion of the amide to the corresponding nitrile. 
Unfortunately, several attempts all failed at the end of 
preparing to the required amide by methods in the 
previous literature. Most of these methods were 
difficult with the consequent reactions, More 
specifically, they had restrictions on the utility and 
applicability, cumbersome synthetic methods and 
high costs in the availability of the reagents. 
However, after several attempts, a method was 
successfully applied to synthesize carboxylic acid 
moiety just simply by acetonitrile in the presence of 
sulfuric acid
13
. In the process of optimizing the 
reaction condition, it was obvious that the time and 
the temperature have significant effects on this 
process. We explored these conditions and found that 
the optimum was treated with MeCN followed by 
sulfuric acid at 95°C. 
To prepare the ultimate compound - vildagliptin, 
we also prepared of 3-amino-1-adamantane alcohol 3. 
Further studies showed that almost all of the 
researchers select dichloromethane to extract the 
target product during the preparation of 3-amino-1-
adamantane alcohol 3. However, the results of several 
experiments demonstrated that the efficiency of 
dichloromethane extraction was considerably low. 
This was because a bottle-neck of dichloromethane to 
restrict the improvement of 3-amino-1-adamantane 
alcohol’s yield. Therefore, it was of great significance 
and practical application to optimize extraction 
technology and the conditions of synthesizing of 3-
amino-1-adamantanol alcohol 3. 
Based on this situation, our group came up with a 
facile step and high yield synthetic method to 
synthesize 3-amino-1-adamantane alcohol. As 
described in Scheme III, the first step was oxidation 
of amantadine hydrochloride 3a by sulfuric acid/nitric 
acid (H2SO4/HNO3) and boric acid (H3BO3) as 
catalyst. The second step was hydrolyzation through 
potassium hydroxide (KOH). The last step was 
extraction of the target compound by ethanol 
extraction technology and the total yield was95%.  
 
Experimental Section 
All reagents and solvents obtained from 
commercial provenance were of laboratory reagent 
grade and used as received. All melting points were 
confirmed by RY-1 capillary melting point meter and 
are uncorrected. The infrared (IR) spectra were 
recorded on a spectrophotometer Nicolet FTIR 5700 
using the KBr pellet technique. 
1
H NMR spectra were 
gained in CDCl3 and DMSO-d6 on Bruker Avance 
600 MHz NMR spectrometer. ESI-MS spectra were 
measured on a Finnigan LCQ Advantage Max 
spectrometer.  
 
Synthesis of (S)-1-(2-chloroacetyl) pyrrolidine-2-
carboxylic acid, 2b 
To a solution of L-proline (10 g, 0.087 mol) in THF 
(200 mL), with the slow drop-wise addition of 
 




Scheme II — A new method to prepare (S)-1-(2-
chloroacetyl) pyrrolidine-2-carbonitrile  
 
 
Scheme III — A new method to prepare 3-amino-1-
adamantane alcohol  
 




chloroacetyl chloride (9.8 mL, 0.129 mol) at 0°C and 
the reaction for 30 minutes. After that, the reaction 
was stirred for 2 hours in 70°C. After completion of 
the reaction, diluted with water (25 mL) and stirred 
for 20 minutes. Then saturated brine (25 mL) and 
ethyl acetate (150 mL) were added and the organic 
layer was collected. The aqueous layer was 
subsequently re-extracted with ethyl acetate (3×50 
mL). The combined organic extracts were dried over 
anhydrous Na2SO4. The filtration was concentrate, 
which was crystallized by the isopropyl ether to 
afford compound 2b (14.87g, 89.0%). m.p. 108–
110.9°C; IR (KBr): 3425, 3050, 2989, 2940, 2811, 




H NMR (600 MHz, 
CDCl3): δ 1.97–2.34 (m, 4H, CH2), 3.57–3.74 (m, 2H, 
CH2), 4.04–4.1 7 (m, 2H, CH2Cl), 4.55–4.64 (m, 1H, 





Synthesis of (S)-1-(2-chloroacetyl) pyrrolidine-2-
carbonitrile, 2 
To a solution of compound 2b (3.0g, 0.016 mol) in 
MeCN (5 mL) was added slowly Concentrated 
sulfuric acid ( 8.5 mL, 0.016 mol) at 95°C and the 
reaction for 5 hr. Then the excess of acetonitrile was 
evaporated to give a residue. After that, CH2Cl2 (20 
mL) and H2O (15 mL) were added to the mixture, and 
the organic layer was separated and the aqueous layer 
was re-extracted with CH2Cl2 (3×30 mL), the 
combined organic layers were dried over anhydrous 
Na2SO4. The filtration was concentrated, and was 
treated with dichloromethane/petroleum ether to give 
the compound 2. (1.04 g, 38.6%). m.p. 52~54°C; IR 





H NMR (600 MHz, CDCl3): δ 2.17–2.39 (m, 
4H, CH2), 3.57–3.62 (m, 1H, CH2N), 3.74–3.78 (m, 
1H, CH2N), 4.06–4.25 (s, 2H, CH2Cl), 4.75–4.86 (m, 




General procedure for the synthesis of impurity  
3-amino-1-adamantane alcohol, 3 
Concentrated sulfuric acid (37.5 mL, 98% w/w 
aqueous solution) was stirred and cooled down to 0-
5°C followed by adding nitric acid (3.75 mL, 65% w/w 
aqueous solution) stirred for 10 minutes, then 
maintained the temperature of 10-20°C. In the second, 
the boric acid was added to the mixture and this 
solution was stirred for 30 minutes, then amantadine 
hydrochloride (3.75g, 0.020mol) was added to solution 
in batches until the solid was decentralized completely, 
the mixture was stirred at 10~20°C for 4 hr. The 
system was transferred to 3-neck flask (250mL), 
slowly added crushed ice (60g) into the mixture and 
stirred for about 30 minutes, until the liquid turned a 
dark green. After that, the mixture was adjusted to 
pH>12 by potassium hydroxide, then stirred at 10-20°C 
for another 4hours to produce large amount of white 
precipitates and was filtered, then used hydrochloric 
acid to adjust the pH of filtrate to 7-9. Afterwards, the 
above reaction solution were concentrated by reduced 
pressure to afford a white powder, and then anhydrous 
(80mL) ethanol was added to the powder, then refluxed 
the mixture for 1 hr. Afterwards, the mixture was 
naturally cooled down to room temperature and 
followed by filtration, the clear filtrate was 
concentrated by reduced pressure to give a white solid, 
which was treated with acetone/ethyl acetate 10 ml 
(7:3, v/v). Subsequently, the mixture was warmed to 
reflux and stirred at 52°C for 1 hr, then filtered the 
mixture and dried to give the target compound 3 as a 
white solid (3.20g, 95%). m.p. 262-264°C; IR (KBr): 





(600 MHz, DMSO-d6): δ 1.41-1.56(m, 6H, CH2), 1.65-
1.70(d, 6H, CH2), 2.20(s, 2H, CH×2), 4.80(s, 1H, OH), 
8.13(br.s, 2H, NH2);
13
C NMR (125 MHz, DMSO-d6):  
δ 67.7, 52.8, 45.2, 44.6, 44.0, 34.8, 30.7; ESI-MS: m/z 
168.2[M+H]
+
. Anal. Calcd for C10H17NO: C, 71.85; H, 
10.18; N, 8.33. Found: C, 71.82; H, 10.14; N, 8.37%. 
 
Conclusion 
In conclusion, we have demonstrated a simple, 
cost effective route for the synthesis of (S)-1-(2-
chloroacetyl) pyrrolidine-2-carbonitrile 2 and a key 
intermediate for the synthesis of vildagliptin 1. On the 
other hand, we provided a new method to prepare 3-
amino-1-adamantane alcohol 3,which used boric acid 
(H3BO3) as catalyst and ethanol extraction technology 
to improve the yield of 3-amino-1-adamantane 
alcohol. They also bring a practical application value 
for synthesis of vildagliptin, compared with 
previously reported methods. Finally, we expect that 
this process would provide a new idea towards 
synthesis of vildagliptin 1. 
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